Oxaliplatin-induced peripheral neuropathy's effects on health-related quality of life of colorectal cancer survivors

Supportive Care in Cancer

Volumn 21, Issue 12, 2013, Pages 3307-3313

  Tofthagen, Cindy ^a,b,c   Donovan, Kristine A ^d   Morgan, Mary Ann ^d   Shibata, David ^d   Yeh, Yating ^c  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF MASSACHUSETTS BOSTON   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Colorectal cancer; Oxaliplatin; Oxaliplatin induced peripheral neuropathy

Indexed keywords

OXALIPLATIN;

ADL DISABILITY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVOR; CENTER FOR EPIDEMIOLOGICAL STUDIES DEPRESSION SCALE; CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY ASSESSMENT TOOL; COLORECTAL CANCER; CROSS-SECTIONAL STUDY; DEPRESSION; DESCRIPTIVE RESEARCH; DISEASE SEVERITY; FEMALE; HUMAN; INSOMNIA SEVERITY INDEX; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SHORT FORM 36; SLEEP DISORDER; VERY ELDERLY;

ADULT; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROTOXICITY SYNDROMES; ORGANOPLATINUM COMPOUNDS; OUTCOME ASSESSMENT (HEALTH CARE); PERIPHERAL NERVOUS SYSTEM DISEASES; QUALITY OF LIFE; QUESTIONNAIRES; SURVIVORS;

EID: 84889087410     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-013-1905-5     Document Type: Article

References (36)

1. ACS (2012) Cancer facts & figures 2012; Available from: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/ document/acspc-031941.pdf. Accessed June 2012
2. NCI (2010) FDA Approval for Oxaliplatin; Available from: http://www.cancer.gov/cancertopics/druginfo/fda-oxaliplatin. Accessed June 2012
3. NCI (2012) Surveillance epidemiology and end results stat fact sheets; Available from: http://seer.cancer.gov/statfacts/html/colorect.html. Accessed June 2012
4. Tofthagen C (2010) Surviving chemotherapy for colon cancer and living with the consequences. J Palliat Med 13(11):1389-1391
5. Krishnan A et al (2005) Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve 32:51-60
6. Choi J et al (2006) Delayed oxaliplatin-associated neurotoxicity following adjuvant chemotherapy for stage qI colon cancer. Anticancer Drugs 17(1):103-105
7. Park SB et al (2011) Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. Oncologist 16(5):708-716
8. Pietrangeli A et al (2006) Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up. Eur Neurol 56(1):13-16
9. Kautio A et al (2008) Amitriptyline in the treatment of chemotherapy induced neuropathic symptoms. J Pain Symptom Manage 35(1):31-39
10. Kopec J et al (2006) Validation of a self-reported neurotoxicity scale in patients with operable colon cancer receiving oxaliplatin. J Support Oncol 4(8):W1-W8
11. Tofthagen C (2010) Patient perceptions associated with chemotherapy induced peripheral neuropathy. Clin J Oncol Nurs 14(3):E22-E28
12. Gore M et al (2005) Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptom Manage 30(4):374-385
13. Gore M et al (2006) Burden of illness in painful diabetic peripheral neuropathy: the patients' perspectives. J Pain 7(12):892-900
14. Zelman DC, Brandenburg NA, Gore M (2006) Sleep impairment in patients with painful diabetic peripheral neuropathy. Clin J Pain 22(8):681-685
15. Almadrones L et al (2004) Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer: a gynecologic oncology group study. Oncol Nurs Forum 31(3):615-623
16. Bakitas MA (2007) Background noise: the experience of chemotherapy-induced peripheral neuropathy. Nurs Res 56(5):323-331
17. Ostchega Y, Donohue M, Fox N (1988) High-dose cisplatin-related peripheral neuropathy. Cancer Nurs 11(1):23-32
18. Tofthagen CS, McMillan SC, Kip KE (2011) Development and psychometric evaluation of the chemotherapy-induced peripheral neuropathy assessment tool. Cancer Nurs 34(4):E10-E20
19. Radloff LS (1977) The CES-D scale: a self report depression scale for research in the general population. Appl Psychol Meas 1:385-401
20. Lewinsohn PM et al (1997) Center for epidemiologic studies depression scale (CES-D) as a screening instrument for depression among community-residing older adults. Psychol Aging 12(2):277-287
21. Morin CM (1993) Insomnia: psychological assessment and management. Guilford Press, New York
22. Savard MH et al (2005) Empirical validation of the insomnia severity index in cancer patients. Psychooncology 14(6):429-441
23. Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30(6):473-483
24. Dunlap B, Paice JA (2006) Chemotherapy-induced peripheral neuropathy: a need for standardization in measurement. J Support Oncol 4(8):398-399
25. Cavaletti G et al (2013) The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol: Off J Eur Soc Med Oncol/ESMO 24(2):454-462
26. Postma TJ et al (2005) The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 41(8):1135-1139
27. Adams RA et al (2011) Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol 12(7):642-653
28. Argyriou AA et al (2013) Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. Cancer 119(2):438-444
29. Argyriou AA et al (2012) Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients. Ann Oncol: Off J Eur Soc Med Oncol/ESMO 23(12):3116-3122
30. Oshinaike O et al (2012) Influence of age and neurotoxic HAART use on frequency of HIV sensory neuropathy. AIDS Research and Treatment 2012:961510
31. Argyriou AA et al (2006) Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy? Support Care Cancer 14(3):223-229
32. Alejandro LM et al (2012) Predicting acute and persistent neuropathy associated with oxaliplatin. Am J Clin Oncol. doi: 10.1097/COC.0b013e318246b50d
33. Lecomte T et al (2006) Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res: Off J Am Assoc Cancer Res 12(10):3050-3056
34. Ruzzo A et al (2007) Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol: Off J Am Soc Clin Oncol 25(10):1247-1254
35. Gamelin L et al (2007) Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway. Clin Cancer Res: Off J Am Assoc Cancer Res 13(21):6359-6368
36. Cavaletti G, Alberti P, Marmiroli P (2011) Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics. Lancet Oncol 12(12):1151-1161